Addressing the issues of reasonable
expectation of success and induced infringement of claims directed
to a method of treatment in a particular patient population based
on the results of a clinical trial, the US Court of Appeals for the
Federal Circuit upheld the district court's finding that the
claimed method was not obvious and that language in the proposed
package inserts induced infringement. Sanofi v. Watson Labs
Inc., Case Nos. 16-2722; -2726 (Fed. Cir., Nov. 9, 2017)
(Taranto, J).
Watson and Sandoz filed abbreviated
new drug applications seeking to market generic versions of
Sanofi's Multaq®. Sanofi sued, alleging infringement of a
patent directed to decreasing a risk of cardiovascular
hospitalization in patients meeting certain clinical criteria by
administering dronedarone—the active ingredient in
Multaq®. After a bench trial, the district court found
infringement and rejected defendants' obviousness argument.
Defendants appealed.